ArticleRenal failure2026
Ginsenoside Rg1 ameliorates renal ischemia-reperfusion injury by inhibiting FABP1-regulated Nrf2/HO-1 pathway.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ginsenoside Rg1 (G-Rg1) can effectively ameliorate lipopolysaccharide-induced renal injury. The impact and mechanism of G-Rg1 in renal ischemia-reperfusion (I/R) injury are not yet understood. This study aimed to examine the role and mechanism of G-Rg1 in kidney I/R injury. The renal I/R injury mice and mouse kidney cells were applied as renal I/R injury models. Researchers analyzed the functions and mechanisms of G-Rg1 using techniques like cell proliferation, apoptosis, clone formation assay, ELISA, HE staining, immunohistochemical staining, Immunofluorescence staining, qRT-PCR, and Western blot analysis. Our findings indicate that G-Rg1 pretreatment protects against renal I/R injury by lowering serum creatinine and urea nitrogen levels, mitigating histological damage and apoptosis, and reducing inflammation and oxidative stress. These beneficial effects were accompanied by the suppression of fatty acid binding protein 1 (FABP1) and heme oxygenase-1 (HO-1) expression and the promotion of nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear translocation. However, the therapeutic effect of G-Rg1 was inhibited by FABP1 overexpression. The mechanism by which G-Rg1 ameliorates renal I/R injury may be related to the inhibition of FABP1 expression and thus regulation of the Nrf2/HO-1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.